Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
0.5100
-0.0099 (-1.90%)
At close: Feb 23, 2026, 4:00 PM EST
0.5200
+0.0100 (1.96%)
After-hours: Feb 23, 2026, 4:00 PM EST
Jupiter Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
17.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 233.28K | -404.76K | -63.44% |
| Dec 31, 2021 | 638.04K | -488.20K | -43.35% |
| Dec 31, 2020 | 1.13M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionJUNS News
- 12 hours ago - Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution - GlobeNewsWire
- 26 days ago - Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users - GlobeNewsWire
- 27 days ago - Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference - Accesswire
- 2 months ago - Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6 - GlobeNewsWire
- 2 months ago - Jupiter Neurosciences to Participate in NobleCon21 - Newsfile Corp
- 4 months ago - Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing - GlobeNewsWire
- 6 months ago - Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador - GlobeNewsWire
- 7 months ago - Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science - GlobeNewsWire